Pharma Mar (PHM) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
13 Nov, 2025Expert backgrounds and patient management
Both experts are medical oncologists managing significant numbers of lung cancer patients in France and Germany, with experience in clinical trials and compassionate use programs for lurbinectedin.
Neither participated in the IMforte trial but have used lurbinectedin via compassionate use.
Strategic vision and leadership
Focused on marine-derived oncology drugs, aiming to remain a global leader in marine medicinal discovery and innovation.
Committed to improving cancer patient outcomes through novel medicines.
Financial performance and stability
Achieved €174.9m in revenues and €13.0m EBITDA in 2024, with €157.0m cash and €1.3bn market cap as of April 2025.
Zepzelca (lurbinectedin) and Yondelis are key revenue drivers, with Zepzelca contributing €120.0m in 2024.
Maintains profitability and a robust balance sheet, supporting ongoing R&D and commercial activities.
Latest events from Pharma Mar
- Lurbinectedin's Phase 3 success in SCLC and strong financials drive global oncology growth.PHM
Corporate presentation20 Mar 2026 - Revenue up 27% and net profit up 187%, driven by Zepzelca and oncology milestones.PHMQ4 202527 Feb 2026
- Net profit rose to €26.2M as revenue, royalties, and licensing income hit record highs.PHMQ4 202412 Feb 2026
- Revenue up 8% and EBITDA up 14%, with strong R&D and positive trial results.PHMQ3 202412 Feb 2026
- Revenue up 1% to €80.8M, net profit €3.5M, royalties up 16%, and R&D spend increased.PHMQ2 202412 Feb 2026
- Recurring revenue up 19%, EBITDA up 60%, and strong cash position at €142.2M.PHMQ1 202512 Feb 2026
- Revenue up 18% to €95.3M, EBITDA €25.1M, driven by oncology sales and licensing gains.PHMQ2 202512 Feb 2026
- Net income and EBITDA surged, fueled by oncology sales, FDA milestones, and licensing deals.PHMQ3 202512 Feb 2026